Zimmer Biomet Holdings Inc.
ZBH evidence brief
What we can confirm
- BioSniper Score:
- 8.1 / 10
- Market Cap:
- $18.46B
- Lead Asset:
- 160/260 suction coagulator
What it means
What to watch
Prepared research question
What matters most for ZBH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZBH
Zimmer Biomet Holdings Inc. (ZBH) is a publicly traded medical device company focused on orthopedic and musculoskeletal health, with a portfolio of approved and pipeline products including bone growth stimulators and joint replacement systems.
Key risk: High debt load
BioSniper Score
Based on 4 of 6 signals
Market Cap
$18.46B
Cash Runway
—
Lead Asset
160/260 suction coagulator
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 346 pipeline candidates · 91 clinical trials for Zimmer Biomet Holdings Inc..
Zimmer Biomet Holdings Inc. (ZBH) is a publicly traded medical device company focused on orthopedic and musculoskeletal health, with a portfolio of approved and pipeline products including bone growth stimulators and joint replacement systems.
- Cash & equivalents of $410.0M as of 2026-06-30 [sec]
- Total revenue of $2,177.0M and net income of $198.3M as of 2026-06-30 [sec]
- Shareholders' equity of $12,623.9M and total debt of $7,479.0M as of 2026-06-30 [sec]
- Pipeline includes approved 'zimmer direct current bone growth stimulator' (invasive bone growth, orthopedic) [pipeline]
- Board committees oversee risks in human capital, ESG, and FDA compliance [sec · filed 2025-04-14]
What works
- Strong financial position with $410.0M cash and $12,623.9M shareholders' equity as of 2026-06-30 [sec]
- Approved product in pipeline (bone growth stimulator) indicates established regulatory pathway [pipeline]
- Board-level risk oversight across quality, regulatory, and human capital areas [sec · filed 2025-04-14]
What to weigh
- Total debt of $7,479.0M is substantial relative to equity as of 2026-06-30 [sec]
- Pipeline includes many early-stage or non-approved candidates (e.g., cls brevius stem, nexgen complete knee) with no disclosed phase [pipeline]
- Risk factors include litigation, regulatory actions, and integration challenges from acquisitions [sec · filed 2025-01-29]
From the filings
Quoted directly from source documents.
Company has approved bone growth stimulator
“Pipeline Candidate: zimmer direct current bone growth stimulator Generic Name: Stimulator, invasive bone growth Indication: Orthopedic Phase: Approved”
Board committees oversee FDA compliance and product quality risks
“The Quality, Regulatory and Technology Committee oversees risks relating to our compliance with laws and regulations enforced by the U.S. Food and Drug Administration ("FDA") and comparable foreign government regulators, including product quality and safety.”
SEC filings · April 14, 2025
Company faces risks from litigation and regulatory actions related to Merger
“the risk of litigation, including shareholder litigation, and/or regulatory actions, including any conditions, limitations or restrictions placed on approvals by any applicable governmental entities, related to the Merger”
SEC filings · January 29, 2025
Risks & what to watch (3)›
Key risks
- High debt load — Total debt of $7,479.0M against $12,623.9M equity as of 2026-06-30 [sec]
- Litigation and regulatory risk — Risk of shareholder litigation and regulatory actions related to Merger [sec · filed 2025-01-29]
- Pipeline uncertainty — Multiple pipeline candidates (e.g., cls brevius stem, nexgen complete knee) lack disclosed phase or approval status [pipeline]
What to watch
- Execution of product portfolio rationalization and restructuring plans [sec_mda · as of 2026-08-05]
- Integration and anticipated benefits from recent acquisitions [sec_mda · as of 2026-08-05]
- Transformation of U.S. and international sales and distribution network [sec_mda · as of 2026-08-05]
Sources: Competitor trials · Pipeline · SEC filings · SEC MD&A · Generated September 30, 2026 · How we verify sources →
Run Zimmer Biomet Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zimmer Biomet Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.81 · 0% dilution
Lead: Approved
346 candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 15, 2026- % of float
- 6.8%
- Days to cover
- 4.0
- Shares short
- 9,996,758
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZBH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Zimmer Biomet Holdings Inc.?
Zimmer Biomet Holdings Inc. (ZBH) is a publicly traded medical device company focused on orthopedic and musculoskeletal health, with a portfolio of approved and pipeline products including bone growth stimulators and joint replacement systems.
Who is the CEO of Zimmer Biomet Holdings Inc.?
Mr. Ivan Tornos is the chief executive officer of Zimmer Biomet Holdings Inc. (ZBH).
Where is Zimmer Biomet Holdings Inc. headquartered?
Zimmer Biomet Holdings Inc. (ZBH) is headquartered in Warsaw, IN, United States.
What therapeutic areas does Zimmer Biomet Holdings Inc. focus on?
Zimmer Biomet Holdings Inc. develops therapies across Oncology, Neurology, Immunology, Ophthalmology, Infectious Disease, Pain, Dermatology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.